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Background: In Germany, immunization against human papillomaviruses (HPV) is free of charge for all females
aged 12 to 17 years. Since HPV infection rates rise soon after first intercourse, immunization against HPV should be
completed before sexual debut. Knowledge of country-specific data on age at first intercourse and related risk
factors is important to optimize prevention of HPV and other sexually transmitted infections. Therefore, the primary
aim of this study was to describe sexual behavior in young women in Germany. Secondary aims were to identify
factors that are (i) associated with younger age at first intercourse and (ii) with HPV vaccine uptake.
Methods: Between 2010 and 2012, we conducted a cross-sectional study among randomly selected women aged
20 to 25 years in Germany. We used a structured, self-administered questionnaire to collect sociodemographic data,
information on sexual habits such as age at first intercourse, and information on HPV vaccine uptake. We used
univariate and multivariate logistic regression analyses to identify factors associated with younger age at first
intercourse and with HPV vaccine uptake.
Results: A total of 823 women (response rate: 14.2%) participated, 785 (95.4%) of which reported having had
intercourse already. 70% of these women experienced first intercourse before the age of 18 years. However, less
than 5% were younger than 14 years at sexual debut. Younger age at first intercourse was independently
associated with a higher number of sexual partners, smoking, and past pregnancies. HPV vaccine uptake was
associated with higher education, whereas smoking and a migrant background reduced the chance of being
vaccinated.
Conclusion: In Germany, only a small proportion of women experienced first intercourse before the age of
14 years. Younger age at first intercourse was associated with behavior that might increase the risk of HPV
infections or other sexually transmitted infections. Therefore, to optimize the HPV vaccination strategy, HPV
vaccination series should be completed before the age of 14 years in Germany.
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Human papillomaviruses (HPV) are the most common
sexually transmitted viruses [1], with a life-time risk of
cervical infection of up to 80% in the female population
[2]. Two safe and effective vaccines covering high-risk
HPV types 16 and 18 are licensed. Since HPV infection
rates rise soon after first intercourse [3,4] and since
HPV vaccines effectiveness is reduced in infected indi-
viduals [5], vaccination series should be completed be-
fore sexual debut. In Germany, the Standing Committee
on Vaccination (STIKO) recommends HPV vaccination
free of charge for all females aged 12 to 17 years since
2007 [6]. Both, the quadrivalent and the bivalent vaccine
are available in Germany.
Several risk factors for HPV transmission have been
identified so far, with high-risk sexual behavior, such as
younger age at first sexual intercourse [1,7] and higher
numbers of present or recent sexual partners [8-10] being
the most important ones. However, few studies have ana-
lyzed sexual behavior in Germany and - to the best of our
knowledge - no study has assessed factors associated with
younger age at first intercourse in Germany so far.
Since national data on sexual behavior are important
to optimize prevention strategies against sexually trans-
mitted infections, the primary aim of this study was to
describe sexual behavior in young women in Germany.
Secondary aims were to identify factors that are associ-
ated (i) with younger age at first intercourse and (ii) with
HPV vaccine uptake.
Methods
Study design and study population
This study was nested in a study designed to determine
HPV prevalence in Germany via home-based self-sampling
[11]. Briefly, we conducted a cross-sectional study among
20 to 25 year old women in Germany between 2010 and
2012. We used a two-step cluster sampling approach
based on the protocol of the German Health Interview
and Examination Survey for Adults [12]: Within selected
sampling points women were randomly selected from local
registration offices. An invitation letter, a self-sampling kit,
and a questionnaire were mailed to each woman who gave
written informed consent. Self-sampling was performed by
cervicovaginal lavage (5 ml volume) with the first gener-
ation Delphi-Screener (Delphi-Bioscience, Scherpenzeel,
The Netherlands) as described previously [13]. The
study was approved by the local ethics committee (Charité,
EA2/028/10) and registered at Deutsches Register
Klinischer Studien (DRKS 00000599).
Questionnaire
With a structured, self-administered questionnaire in the
German language we obtained information on sociode-
mographic factors, data on sexual behavior (such as ageat first intercourse and number of lifetime and recent
(i.e. in the previous 12 months) sexual partners), medical
and smoking history, contraceptive use, past pregnancies,
past delivery of a child, as well as HPV-vaccine uptake
(time of vaccination and number of doses). The question-
naire has been developed by the Robert Koch Institute
and was previously used in another study [14]. Details
about the questionnaire and definitions are described
elsewhere [11]. Data from the questionnaires were self-
reported and not validated.
Statistical analysis
We calculated proportions on young age at first inter-
course, contraceptive use and past pregnancies with
corresponding 95% confidence intervals (95% CI). We
evaluated the lifetime number of sexual partners by esti-
mating the median, range and interquartile bounds (IQB).
For comparison of proportions of categorical variables, we
used chi-squared test and Fisher’s exact test, and Student’s
t-test for numerical variables. Differences between three
age groups (20–21, 22–23 and 24–25 years) were assessed
by the Kruskal-Wallis-test for categorical variables and by
analysis of variance (ANOVA) for continuous variables.
The age cut-off for ‘young’ age at first intercourse was
defined as the lower quartile (age ≤ 14) and a ‘high’ num-
ber of lifetime sexual partners was defined as the upper
quartile (≥ 7 partners) in the respective variable distribu-
tion. For assessing factors associated with HPV vaccine
uptake, women with at least one HPV vaccine dose were
defined as “vaccinated”.
In order to identify factors associated with (i) young age
at first intercourse and (ii) HPV vaccine uptake, we con-
ducted univariate analyses for all binary or categorical ex-
posure variables and calculated odds ratios (OR) and 95%
confidence intervals (95% CI). We then used multivariate
logistic regression analysis and included variables with a
p-value <0.1 in univariate analysis. In addition, we included
important potential confounding factors on the basis of the
current literature. Two-sided hypothesis tests were performed
and a p-value of less than 0.05 was considered as statistically
significant. Missing data were treated as such and not im-
puted. We used the statistical software package STATA,
version 11 (STATA Corp., College Station, TX, USA).
Representativeness of study population
We used data of the German Federal Statistical Office
(as of 31 December 2011 [15]) to compare characteristics
of our study population with the general German female
population of the same age.
Results
Overall study population
Overall, 823 out of 5805 women with a valid postal ad-
dress (14.2%) completed the questionnaire and were
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pants was 22.6 years (standard deviation (SD) = 1.6).
Key characteristics of the study population compared
to the general female population in Germany of the
same age group are presented in Table 1.
Sexual behavior
Overall, 95.4% (95% CI, 93.7-96.7%) had experienced
sexual debut at the time of the study. More than half of
the women were 16 years or older at sexual debut,
whereas only 4.6% (95% CI, 3.3-6.3%) were younger than
14 years (Table 2). 73.5% (95% CI, 70.3-76.5%) were living
in a relationship and 69.6% (95% CI, 66.5-72.8%) reported
having had just one sexual partner in the previous
12 months. The proportion of women with more than one
sexual partner in the last 12 months was significantly
higher among women not living in a relationship as
compared to those living in a relationship (35.6% vs. 16.3%,
p-value < 0.01).
Factors associated with young age at first intercourse
17.2% (95% CI, 14.7-20.0%) of sexually active women re-
ported that they experienced first intercourse before or at
age of 14 years (Table 2). More than half of the women
were older than 15 years at sexual debut and one fourth
was older than 17 years. In univariate analysis younger age
at first intercourse (defined as ≤ 14 years) was independ-
ently associated with lower educational status, current
smoking, a higher number of recent and lifetime sexual
partners, bisexual experience, usage of contraceptive pill,
past pregnancy, and genital warts (data not shown).
The final multivariate model indicated that current
smoking, a higher number of sexual partners, and past
pregnancy were independently associated with youngFigure 1 Flow chart of the study.age at first intercourse (Table 3). In addition, women
with younger age at sexual debut were more likely to
have bisexual experience and to have used the contra-
ceptive pill. Adjusting for age did not substantially
affect the model.Contraception and pregnancy
A total of 92.7% (95% CI, 90.1-94.5%) women reported
usage of any type of contraception, with the contracep-
tive pill and condoms being the most common ones
(Table 2). 10.8% (95% CI, 8.7-12.9%) of the participants
had ever used a vaginal ring and 1.5% (95% CI, 0.6-2.3%)
an implant. Overall, 80.8% (95% CI, 77.9-83.4%) of women
stated that they would always use condoms during a
one-night stand. However, the probability of consistent
condom use decreased with an increasing number of a
woman's lifetime sexual partners (p-value <0.01). The
proportion of women with a previous pregnancy and
who delivered a child was 8.6% (95% CI, 6.6-10.4%) and
5.6% (95% CI, 4.0-7.2%), respectively.HPV vaccine uptake
Two hundred thirty-four out of 772 participants (30.3%,
95% CI, 27.1-33.7%) with information on HPV vaccin-
ation status received at least one dose of an HPV vaccine
and 206 (26.7%, 95% CI, 23.6-29.9%) received the full
course. Statistically, vaccinated women were significantly
younger than unvaccinated women (mean age, 21.5 years
(SD = 1.5) vs. 23.0 years, (SD = 1.4), p-value <0.01).
Fifty-six (30.1%, 95% CI, 23.6-37.2%) out of 186 women
received the first dose of vaccination before their first
intercourse. Nineteen (3.5%, 95%, 2.1-5.5%) out of 538
unvaccinated women reported that they were still planning








% (95% CI) %
Residency
Western federal states 82.5 (79.7-85.0) 83.71
Eastern federal states 18.3 (17.5-20.3) 16.31
Living in a city with
< 500,000 inhabitants 83.0 (80.0-85.6) 80.5
≥ 500,000 inhabitants 16.9 (14.4-19.7) 19.5
Current smoker
No 69.9 (66.6-73.0) 67.2
Yes 30.1 (26.9-33.4) 32.8
Migrant background
No 85.9 (83.3-88.2) 78.0
Yes 14.1 (11.8-16.7) 22.0
Educational status
Low 5.8 (4.3-7.6) 22.2
Medium 28.6 (25.5-31.8) 32.8
High 65.6 (62.3-68.9) 44.9
1comparison group: women aged 20–25 years.
95% CI, 95% confidence interval.




Variable/Category n/N % (95% CI)
Living in a partnership 604/822 73.5 (70.3-76.5)
Age at first intercourse (years)
No sexual intercourse 38/823 4.6 (3.2-6.1)
< 13 8/823 1.0 (0.3-1.6)
13 30/823 3.6 (2.4-4.9)
14 104/823 12.6 (10.4-14.9)
15 155/823 18.8 (16.2-21.5)
16 149/823 18.1 (15.5-20.7)
17 125/823 15.2 (12.7-17.6)
≥18 214/823 26.0 (23.0-29.0)
Lifetime no. of sexual partners
0 38/819 4.6 (3.2-6.1)
1 265/819 19.6 (16.9-22.4)
2-3 264/819 24.4 (21.5-27.4)
4-6 169/819 26.2 (23.2-29.3)
≥ 7 83/819 25.0 (22.1-28.0)
Median lifetime no. of partners (IQB) 819 4 (2–7)
Mean (SD; range) 5.2 (6.1;0–80)
Recent sexual partners1
0 72/820 8.8 (6.8-10.7)
1 571/820 69.6 (66.5-72.8)
≥ 2 177/820 21.6 (18.8-24.4)
Bisexual experience 37/786 4.7 (3.2-6.2)
Any contraceptive use (ever) 763/823 92.7 (90.1-94.5)
Contraceptive method
Pill (ever) 734/823 89.2 (87.1-91.3)
Pill (current use1) 416/823 50.6 (47.1-54.0)
Condoms (ever) 568/823 69.0 (65.8-72.2)
Condom use during ONS 660/817 80.8 (77.9-83.4)
Vaginal ring (ever) 89/823 10.8 (8.7-12.9)
Implant (ever) 12/823 1.5 (0.6-2.3)
History of genital warts 19/801 2.4 (1.3-3.4)
Ever pregnant 70/821 8.5 (6.6-10.4)
Delivery of a child 46/817 5.6 (4.0-7.2)
IQB interquartile bounds; SD standard deviation; 95% CI 95% confidence.
Interval; 1 in the past 12 months.
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one, already had had their sexual debut.
In multivariate analysis HPV vaccine uptake was inde-
pendently associated with younger age and a higher edu-
cational status. Vice versa, active smoking and migrant
background were associated with a lower chance of be-
ing vaccinated (Table 4).
Discussion
In this study, more than 70% of women experienced
their first intercourse before age of 17, but less than 5%
before age of 14. Factors strongly associated with youn-
ger age at first intercourse were a high number (≥ 7) of
sexual partners during lifetime, current smoking and a
past pregnancy. HPV vaccine uptake was higher in
women with higher educational status, whereas uptake
was lower in smokers and in women with a migrant
background.
National data about sexual behavior in young adults is
scarce in Germany. To optimize prevention strategies
against sexually transmitted infections, these data is ur-
gently needed. Our results on age at first intercourse are
comparable with data obtained in other studies: Crochard
et al. reported results from seven European countries
where the majority of young women experienced sexual
debut between 15 and 18 years (1st to 3rd quartile); lessthan 5% of girls in this study (4.6% in our study) were
younger than 14 years [16]. In a large population-based
study in four Nordic countries conducted 2004–2005,
Jensen and colleagues found that 2.7% ─ 4.7% of women
aged 18 to 25 years had experienced sexual debut at, or
before age of 13 years, and 10.6% ─ 16% before the age of
15, respectively [17]. Finally, a representative survey on
Table 3 Adjusted odds ratio (OR) and 95% confidence
intervals for factors associated with young age at first




Age at first intercourse ≤ 14 vs. > 14 years
Adjusted OR
n % pos (95% CI) p
Current smoker
No 539 11.7 1 -
Yes 244 32.4 2.3 (1.5-3.6) <0.01
Educational status
Low 46 41.3 1 -
Medium 225 24.0 0.5 (0.2-1.1) 0.08
High 510 13.3 0.3 (0.2-0.7) 0.01
Lifetime no. of sexual partners
1 161 4.3 1 -
2-3 200 11.5 2.5 (1.0-6.5) 0.05
4-6 215 20.8 4.6 (1.9-11.2) <0.01
≥ 7 205 30.2 5.0 (2.0-12.4) <0.01
Bisexual expierience
No 738 16.1 1 -
Yes 37 51.3 3.2 (1.5-6.8) <0.01
Contraceptive pill (ever)
No 62 9.7 1
Yes 723 18.9 2.7 (1.0-7.0) 0.05
Past pregnancy
No 714 15.5 1 -
Yes 70 44.3 3.0 (1.6-5.4) <0.01
OR odds ratio; 95% CI 95% confidence interval.
Table 4 Adjusted odds ratio (OR) and 95% confidence









Age (years) 758 - 0.5 (0.4-0.6) < 0.01
Current smoker
No 547 35.5 1 -
Yes 223 17.9 0.4 (0.3-0.7) <0.01
Migrant background
No 657 32.9 1 -
Yes 108 13.0 0.4 (0.2-0.8) <0.01
Educational status
Low 37 10.8 1 -
Medium 219 27.4 3.8 (1.2-12.3) 0.03
High 511 33.1 4.7 (1.5-14.8) <0.01
ORodds ratio; 95% CI 95% confidence interval.
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2009 revealed that 66% of girls have had first sexual inter-
course before the age of 18 (74% in our study) and 7% be-
fore the age of 15 (17% in our study) [18].
The use of contraceptives was very common in our
study population, with the contraceptive pill and con-
doms being the most popular ones. 80% of participants
reported that they would use condoms regularly during
one-night stands. These findings might be a positive ef-
fect of an ongoing public campaign about condom use
and prevention of sexually transmitted infections in
Germany [19]. However, the probability of consistent
condom use decreased with an increasing number of a
woman's lifetime sexual partners. Regarding prevention
strategies against sexually transmitted infections, bene-
fits of consistent condom use needs to be addressed
continuously towards young adults. Since condom use
may imply a lesser protection against HPV infection than
against several other sexually transmitted infections,
[20,21] HPV vaccination needs to be promoted as well.
The fact that younger age at first intercourse is associ-
ated with risky (sexual) behavior is corroborated by
other studies that have shown that early intercourse is
associated with higher numbers of sexual partners, bi-
sexual experience, smoking and early pregnancy later in
life [22-25]. In addition, women with a higher number of
sexual partners [17] also had less consistent condom
use, which in turn increased the risk of acquiring sexual
transmitted infections [23,24], including HPV. Several
large population-based studies [8,9,11,26] found that a
higher number of sexual partners independently in-
creased the risk for HPV infection and, in consequence,
increased the risk of pre-cancer and cancer lesions [27].
To this end, women with younger age at first intercourse
are at particularly high risk for HPV infection and have
the greatest need of getting vaccinated at younger age.
In line with current literature, HPV vaccine uptake was
associated with higher education [28-31]. Interestingly,
women with a migrant background had a lower chance of
being vaccinated. A Canadian study assessing awareness,
knowledge and attitudes towards the HPV vaccines found
that awareness was higher in Caucasian compared to non-
Caucasian women [32]. If the effect in our study is real
and not affected by participation bias, efforts are needed
to understand possible barriers against HPV vaccination
in women with migrant background and to increase
vaccine-uptake in this population. However, when factors
associated with HPV vaccination are interpreted, the age
of study participants (with regard to sexual debut) and
endorsement date of the recommendation for HPV vac-
cination have to be taken into account. Women aged
25 years at the time of our study were 20–22 years old
when HPV vaccination was adopted into the national
immunization schedule in Germany. Therefore, it is not
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the vaccine after sexual debut.
The findings of our survey have important implications
for the target population for HPV vaccination in Germany:
since rates of HPV rise soon after first intercourse and
since HPV vaccination is less effective in infected individ-
uals [3,4], HPV vaccination is recommended to be admin-
istered before sexual intercourse [33]. According to our
data, HPV vaccination series in Germany should be com-
pleted before the age of 14 years, when the majority of
girls had not experienced sexual debut. Physicians should
be aware of these data when discussing the optimal time
point of the HPV vaccination with their young patients
and their parents. Finally, it should be considered, whether
the HPV vaccination strategy could be optimized by pre-
poning the recommended age at which HPV vaccination
should be initiated.
Limitations
Some limitations of our study need to be taken into ac-
count. First, the response rate was low (14%) with the
potential of introducing participation bias. Since this
study was implemented in a population based survey to
evaluate HPV prevalence using a self-sampling method,
the response rate was comparable to a similar study
[34]. However, women with a migrant background were
underrepresented and those with a higher education
were overrepresented. As educational status was inde-
pendently associated with young age at first intercourse,
it is possible that the true proportion of these women is
higher than estimated by our study. However, other
characteristics of our study sample, such as place of resi-
dency, living in a city, and smoking behavior were com-
parable to the German female population of similar age
groups. Second, information on sexual behavior and vac-
cination status were self-reported and could be subject
to misclassification. Third, due to the sensitive nature of
the topic on sexual behavior, social desirability bias can-
not be excluded. Although anonymity and confidentiality
was ensured, women might have had the tendency to
give more “desirable” answers with for example a lower
number of sexual lifetime partners or an older age at
first intercourse. Forth, a long time interval since rele-
vant exposures (e.g., time at first intercourse) may have
led to miscalculation by participants and may have influ-
enced the magnitude of relative risk estimates.
Conclusion
Although hampered by its low response rate, our study
indicate that in Germany the majority of young women
experienced first sexual intercourse before the age of
18 years, but only a small proportion before the age of
14 years. Usage of the contraceptive pill and condoms
was common in our study population. However, condomuse may imply lesser protection against HPV than
against other sexually transmitted infections, therefore
HPV vaccination needs to be promoted as well. Since
younger age at first intercourse was associated with be-
havior that might increase the risk of HPV infections,
HPV vaccination series should be completed before the
age of 14 years in Germany.
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